Discovering New Insights Into Anorexia Nervosa: Influence of MicrObial DysbiosiS (DIAMOnDS) — DIAMOnDS  

Anorexia Nervosa Clinical Trial

Official title: Discovering New Insights Into Anorexia Nervosa: Influence of MicrObial DysbiosiS (DIAMOnDS)

Status Recruiting

Clinical Trial Summary

This study will investigate the link between the gut microbiota, the occurrence of the central adiposity phenotype, and the patients' fear to regain weight in anorexia nervosa.

Clinical Trial Description

Excessive concerns about body shape and intense fear of becoming fat are among the core features of Anorexia Nervosa (AN). During refeeding, patients commonly report a disproportionate deposition of fat in the abdomen which could represent an obstacle for weight gain. It is not known whether these complaints are caused by dysmorphophobia or if the distribution of fat during refeeding could really not be uniform. Indeed, a "central adiposity phenotype" has already been objectified by anthropometric measures or imaging, with a higher proportion of visceral fat accumulated in the abdomen during the refeeding. This phenomenon could exacerbate body shape concerns and ultimately lead to an elevated risk of resistance to treatment and/or relapse. The present research project aims to explore the mechanisms that underlie these difficulties, especially by investigating the link between the gut microbiota (both composition and products) and the occurrence of the central adiposity phenotype, and the patients' fear to regain weight. Patients with severe to extreme anorexia nervosa admitted at hospital for refeeding will be included. To describe patients included, a short clinical examination will be performed during the first week after inclusion, including several measures (sociodemographic data, medical history, history of eating disorders, current symptomatology of AN, and a dietary survey). To investigate the gut microbiota biomarkers in stool (composition, diversity and richness, and metabolites), stool samples will be collected during the first week after inclusion and during the last week before discharge, together with information useful to stool sample analyses (related to stool consistency, intestinal transit, abdominal pain or discomfort, and psychoactive substance and prebiotics use). In addition, blood samples will be collected during the first week after inclusion and during the last week before discharge, to investigate : (i) the levels of metabolites of the gut microbiota in blood, (ii) the nutritional and inflammation status. To investigate central adiposity phenotype, anthropometric data will be collected weekly throughout the hospitalisation (including during the first and last week), and dual-energy X-ray absorptiometry (DXA) will be administered during the first week after inclusion and during the last week before discharge. To investigate clinical outcomes, several self-reported questionnaires will be completed by the patients during the first week after inclusion and during the last week before discharge, including cognitive and behavioral characteristics of AN, body shape concerns, level of physical hyperactivity, anxiety and depression. Moreover, treatment-related data, hormonal situation and eating disorder episodes will be collected during weekly follow-up visits. Finally, a short clinical examination will be performed during the last week before discharge to collect the whole duration of hospitalisation and the current symptomatology of eating disorders. This will allow to compare gut microbiota biomarkers (composition, diversity and richness, and metabolites) between patients with and without occurrence of the central adiposity phenotype during refeeding, to estimate the frequency of the occurrence of the central adiposity phenotype during refeeding, to characterise the gut microbiota biomarkers of patients with severe to extreme anorexia nervosa, to investigate the association between the occurrence of the central adiposity phenotype during the refeeding and clinical outcomes of the hospitalisation, to identify the gut microbiota biomarkers associated with clinical outcomes of the hospitalisation, and to estimate a mediation model to explain the links between the gut microbiota biomarkers and clinical outcomes, through the occurrence of the central adiposity phenotype and the change in body shape concerns.. An ancillary study will also be perfomed for patients participating to the DIAMOnDS study and accepting to participate to this ancillary study aimed at investigating the association between microbial and metabolic biomarkers of the gut microbiota (data collected in the DIAMOnDS study) and osteoporosis at inclusion. ;

Related Conditions & MeSH terms

• Anorexia
• Anorexia Nervosa
• Dysbiosis

• NCT number: NCT06043154
• Study type: Interventional
• Source: Nantes University Hospital
• Contact: Marie GRALL-BRONNEC, Professor
• Phone: +33 2 40 84 76 20
• Email: marie.bronnec@chu-nantes.fr
• Status: Recruiting
• Phase: N/A
• Start date: February 22, 2024
• Completion date: February 28, 2026